Epithelial Cell-Derived a Disintegrin and Metalloproteinase-17 Confers Resistance to Colonic Inflammation Through EGFR Activation

EBioMedicine

Volumn 5, Issue , 2016, Pages 114-124

  Shimoda, Masayuki ^a   Horiuchi, Keisuke ^a   Sasaki, Aya ^a   Tsukamoto, Tetsuya ^b   Okabayashi, Koji ^a   Hasegawa, Hirotoshi ^a   Kitagawa, Yuko ^a   Okada, Yasunori ^a,c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

A disintegrin and metalloproteinase 17 (ADAM17); Epidermal growth factor receptor (EGFR); Epithelial barrier; Goblet cell; Ulcerative colitis

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE 17 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; METALLOPROTEINASE; UNCLASSIFIED DRUG; ADAM17 PROTEIN, MOUSE; DEXTRAN SULFATE; EGFR PROTEIN, MOUSE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELL REGENERATION; COLITIS; CONTROLLED STUDY; DISEASE RESISTANCE; DOT HYBRIDIZATION; GENE SILENCING; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; COLON; DISEASE MODEL; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; GOBLET CELL; HUMAN; METABOLISM; PATHOLOGY; ULCERATIVE COLITIS;

ADAM17 PROTEIN; ANIMALS; CELL PROLIFERATION; COLITIS, ULCERATIVE; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; ERBB RECEPTORS; GENE EXPRESSION REGULATION; GOBLET CELLS; HUMANS; INFLAMMATION; MICE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84958554564     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.02.007     Document Type: Article

References (48)

1. Abraham C., Cho J.H. Inflammatory bowel disease. N. Engl. J. Med. 2009, 361:2066-2078.
2. Ananthakrishnan A.N. Epidemiology and risk factors for IBD. Nat. Rev. Gastroenterol. Hepatol. 2015, 12:205-217.
3. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., Cerretti D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
4. Blaydon D.C., Biancheri P., Di W.L., Plagnol V., Cabral R.M., Brooke M.A., Van Heel D.A., Ruschendorf F., Toynbee M., Walne A., O'toole E.A., Martin J.E., Lindley K., Vulliamy T., Abrams D.J., Macdonald T.T., Harper J.I., Kelsell D.P. Inflammatory skin and bowel disease linked to ADAM17 deletion. N. Engl. J. Med. 2011, 365:1502-1508.
5. Blobel C.P. ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell Biol. 2005, 6:32-43.
6. Brandl K., Sun L., Neppl C., Siggs O.M., Le Gall S.M., Tomisato W., Li X., Du X., Maennel D.N., Blobel C.P., Beutler B. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19967-19972.
7. Brooke M.A., Etheridge S.L., Kaplan N., Simpson C., O'toole E.A., Ishida-Yamamoto A., Marches O., Getsios S., Kelsell D.P. iRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function. Hum. Mol. Genet. 2014, 23:4064-4076.
8. Brynskov J., Foegh P., Pedersen G., Ellervik C., Kirkegaard T., Bingham A., Saermark T. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002, 51:37-43.
9. Cesaro A., Abakar-Mahamat A., Brest P., Lassalle S., Selva E., Filippi J., Hebuterne X., Hugot J.P., Doglio A., Galland F., Naquet P., Vouret-Craviari V., Mograbi B., Hofman P.M. Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G1332-G1343.
10. Chalaris A., Adam N., Sina C., Rosenstiel P., Lehmann-Koch J., Schirmacher P., Hartmann D., Cichy J., Gavrilova O., Schreiber S., Jostock T., Matthews V., Hasler R., Becker C., Neurath M.F., Reiss K., Saftig P., Scheller J., Rose-John S. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J. Exp. Med. 2010, 207:1617-1624.
11. Charbonneau M., Harper K., Grondin F., Pelmus M., Mcdonald P.P., Dubois C.M. Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme/ADAM17 expression by synovial cells. J. Biol. Chem. 2007, 282:33714-33724.
12. Chassaing B., Aitken J.D., Malleshappa M., Vijay-Kumar M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 2014, 104. (Unit 15 25).
13. Clausen B.E., Burkhardt C., Reith W., Renkawitz R., Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999, 8:265-277.
14. Danese S., Colombel J.F., Peyrin-Biroulet L., Rutgeerts P., Reinisch W. Review article: the role of anti-TNF in the management of ulcerative colitis - past, present and future. Aliment. Pharmacol. Ther. 2013, 37:855-866.
15. D'argenio G., Calvani M., Della Valle N., Cosenza V., Di Matteo G., Giorgio P., Margarucci S., Petillo O., Jori F.P., Galderisi U., Peluso G. Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis. Gut 2005, 54:496-502.
16. Dong F., Zhang L., Hao F., Tang H., Wang Y. Systemic responses of mice to dextran sulfate sodium-induced acute ulcerative colitis using 1H NMR spectroscopy. J. Proteome Res. 2013, 12:2958-2966.
17. Duffy M.J., Mullooly M., O'donovan N., Sukor S., Crown J., Pierce A., Mcgowan P.M. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?. Clin. Proteomics 2011, 8:9.
18. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Mol. Asp. Med. 2008, 29:258-289.
19. Egger B., Procaccino F., Lakshmanan J., Reinshagen M., Hoffmann P., Patel A., Reuben W., Gnanakkan S., Liu L., Barajas L., Eysselein V.E. Mice lacking transforming growth factor alpha have an increased susceptibility to dextran sulfate-induced colitis. Gastroenterology 1997, 113:825-832.
20. Egger B., Carey H.V., Procaccino F., Chai N.N., Sandgren E.P., Lakshmanan J., Buslon V.S., French S.W., Buchler M.W., Eysselein V.E. Reduced susceptibility of mice overexpressing transforming growth factor alpha to dextran sodium sulphate induced colitis. Gut 1998, 43:64-70.
21. Farmer R.G., Easley K.A., Rankin G.B. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig. Dis. Sci. 1993, 38:1137-1146.
22. Feng Y., Tsai Y.H., Xiao W., Ralls M.W., Stoeck A., Wilson C.L., Raines E.W., Teitelbaum D.H., Dempsey P.J. Loss of ADAM17-mediated tumor necrosis factor alpha signaling in intestinal cells attenuates mucosal atrophy in a mouse model of parenteral nutrition. Mol. Cell. Biol. 2015, 35:3604-3621.
23. Franzke C.W., Cobzaru C., Triantafyllopoulou A., Loffek S., Horiuchi K., Threadgill D.W., Kurz T., Van Rooijen N., Bruckner-Tuderman L., Blobel C.P. Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. J. Exp. Med. 2012, 209:1105-1119.
24. Guinea-Viniegra J., Zenz R., Scheuch H., Jimenez M., Bakiri L., Petzelbauer P., Wagner E.F. Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17. J. Clin. Invest. 2012, 122:2898-2910.
25. Hall K.C., Hill D., Otero M., Plumb D.A., Froemel D., Dragomir C.L., Maretzky T., Boskey A., Crawford H.C., Selleri L., Goldring M.B., Blobel C.P. ADAM17 controls endochondral ossification by regulating terminal differentiation of chondrocytes. Mol. Cell. Biol. 2013, 33:3077-3090.
26. Horiuchi K., Kimura T., Miyamoto T., Takaishi H., Okada Y., Toyama Y., Blobel C.P. Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J. Immunol. 2007, 179:2686-2689.
27. Huang B.L., Chandra S., Shih D.Q. Skin manifestations of inflammatory bowel disease. Front. Physiol. 2012, 3:1-13.
28. Kawasaki T., Matsuzaki K., Horiuchi K., Toyama Y., Takaishi H. A novel ADAM inhibitor, S-44029, supresses osteoclastogenesis in vitro. J. Bone Miner. Res. 2006, 21:S394.
29. Khokha R., Murthy A., Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat. Rev. Immunol. 2013, 13:649-665.
30. Kuhn R., Schwenk F., Aguet M., Rajewsky K. Inducible gene targeting in mice. Science 1995, 269:1427-1429.
31. La Marca R., Cerri F., Horiuchi K., Bachi A., Feltri M.L., Wrabetz L., Blobel C.P., Quattrini A., Salzer J.L., Taveggia C. TACE (ADAM17) inhibits Schwann cell myelination. Nat. Neurosci. 2011, 14:857-865.
32. Laukoetter M.G., Nava P., Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J. Gastroenterol. 2008, 14:401-407.
33. Lichtenstein G.R., Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm. Bowel Dis. 2010, 16:338-346.
34. Mochizuki S., Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007, 98:621-628.
35. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 2008, 8:929-941.
36. Okamoto R., Watanabe M. Cellular and molecular mechanisms of the epithelial repair in IBD. Dig. Dis. Sci. 2005, 50(Suppl. 1):S34-S38.
37. Ordas I., Eckmann L., Talamini M., Baumgart D.C., Sandborn W.J. Ulcerative colitis. Lancet 2012, 380:1606-1619.
38. Palazuelos J., Crawford H.C., Klingener M., Sun B., Karelis J., Raines E.W., Aguirre A. TACE/ADAM17 is essential for oligodendrocyte development and CNS myelination. J. Neurosci. 2014, 34:11884-11896.
39. Peschon J.J., Slack J.L., Reddy P., Stocking K.L., Sunnarborg S.W., Lee D.C., Russell W.E., Castner B.J., Johnson R.S., Fitzner J.N., Boyce R.W., Nelson N., Kozlosky C.J., Wolfson M.F., Rauch C.T., Cerretti D.P., Paxton R.J., March C.J., Black R.A. An essential role for ectodomain shedding in mammalian development. Science 1998, 282:1281-1284.
40. Peterson L.W., Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 2014, 14:141-153.
41. Sahin U., Blobel C.P. Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. FEBS Lett. 2007, 581:41-44.
42. Sahin U., Weskamp G., Kelly K., Zhou H.M., Higashiyama S., Peschon J., Hartmann D., Saftig P., Blobel C.P. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 2004, 164:769-779.
43. Scheller J., Chalaris A., Garbers C., Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011, 32:380-387.
44. Shimoda M., Khokha R. Proteolytic factors in exosomes. Proteomics 2013, 13:1624-1636.
45. Shimoda M., Hashimoto G., Mochizuki S., Ikeda E., Nagai N., Ishida S., Okada Y. Binding of ADAM28 to P-selectin glycoprotein ligand-1 enhances P-selectin-mediated leukocyte adhesion to endothelial cells. J. Biol. Chem. 2007, 282:25864-25874.
46. Shimoda M., Principe S., Jackson H.W., Luga V., Fang H., Molyneux S.D., Shao Y.W., Aiken A., Waterhouse P.D., Karamboulas C., Hess F.M., Ohtsuka T., Okada Y., Ailles L., Ludwig A., Wrana J.L., Kislinger T., Khokha R. Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state. Nat. Cell Biol. 2014, 16:889-901.
47. Van Klinken B.J., Oussoren E., Weenink J.J., Strous G.J., Buller H.A., Dekker J., Einerhand A.W. The human intestinal cell lines Caco-2 and LS174T as models to study cell-type specific mucin expression. Glycoconj. J. 1996, 13:757-768.
48. Wirtz S., Neufert C., Weigmann B., Neurath M.F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007, 2:541-546.